These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20349264)

  • 1. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
    Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
    Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
    Mita MM; Ochoa L; Rowinsky EK; Kuhn J; Schwartz G; Hammond LA; Patnaik A; Yeh IT; Izbicka E; Berg K; Tolcher AW
    Ann Oncol; 2006 Feb; 17(2):313-21. PubMed ID: 16322117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
    O'Brien SM; Cunningham CC; Golenkov AK; Turkina AG; Novick SC; Rai KR
    J Clin Oncol; 2005 Oct; 23(30):7697-702. PubMed ID: 16186597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential therapeutic applications of oblimersen in CLL.
    Koziner B
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
    Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
    Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
    Hubbard J; Erlichman C; Toft DO; Qin R; Stensgard BA; Felten S; Ten Eyck C; Batzel G; Ivy SP; Haluska P
    Invest New Drugs; 2011 Jun; 29(3):473-80. PubMed ID: 20082116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Chi K; Kuhn J; Gleave M; Patnaik A; Takimoto C; Schwartz G; Thompson I; Berg K; D'Aloisio S; Murray N; Frankel SR; Izbicka E; Rowinsky E
    Clin Cancer Res; 2005 May; 11(10):3854-61. PubMed ID: 15897586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
    Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.
    Venugopal B; Awada A; Evans TR; Dueland S; Hendlisz A; Rasch W; Hernes K; Hagen S; Aamdal S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):785-92. PubMed ID: 26289594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
    Adjei AA; Dy GK; Erlichman C; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton PJ; Watanabe T; Geary RS; Holmlund J; Dorr FA
    Clin Cancer Res; 2003 Jan; 9(1):115-23. PubMed ID: 12538459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
    Raab R; Sparano JA; Ocean AJ; Christos P; Ramirez M; Vinciguerra V; Kaubisch A
    Am J Clin Oncol; 2010 Feb; 33(1):61-5. PubMed ID: 19738454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.
    Liu G; Kolesar J; McNeel DG; Leith C; Schell K; Eickhoff J; Lee F; Traynor A; Marnocha R; Alberti D; Zwiebel J; Wilding G
    Clin Cancer Res; 2008 May; 14(9):2732-9. PubMed ID: 18451239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
    Paz-Ares L; Forster M; Boni V; Szyldergemajn S; Corral J; Turnbull S; Cubillo A; Teruel CF; Calderero IL; Siguero M; Bohan P; Calvo E
    Invest New Drugs; 2017 Apr; 35(2):198-206. PubMed ID: 27873130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.
    Malik L; Zwiebel A; Cooper J
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):533-539. PubMed ID: 30022224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.